GeNeuro’s ANGEL-MS Phase 2b extension study confirms and extends the neuroprotective effects of temelimab in MS
Data Supports Temelimab's Potential to Treat Disease Progression in MS
- Long-term neuroprotective effects confirmed in patients treated up to two years
- Sustained benebits on cortical and thalamic atrophy and myelin integrity
- Encouraging, dose dépendent effects seen on clinical measures of disease progression
- Excellent tolerability continued to be observed, with no dose-limiting safety signals
- GeNeuro will hold a conference call and webcast today Tuesday, March 12 at 2:30 pm CET / 9:30 am EDT, to share results
Geneva, Switzerland, 12 March 2019 – 07:00am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), type-1 diabetes (T1D) and amyotrophic lateral sclerosis (ALS), today announced positive results from the ANGEL-MS study of its lead product, temelimab in MS. Temelimab is a humanized, monoclonal antibody designed to neutralize pHERV-W, a pathogenic protein thought to be a causal factor in the development of multiple sclerosis.